Skip to Content
Merck

Skip To

P-075

Primidone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C12H14N2O2
CAS Number:
Molecular Weight:
218.25
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-659-6
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CCC1(C(=O)NCNC1=O)c2ccccc2

InChI

1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)

InChI key

DQMZLTXERSFNPB-UHFFFAOYSA-N

General description

Primidone, marketed as the barbiturate Mysoline®, Prysoline, or Liskantin®, is an anticonvulsant used in the treatment of partial and generalized seizures. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications in clinical toxicology or therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Liskantin is a registered trademark of Desitin Arzneimittel GmbH
Mysoline is a registered trademark of Valeant Pharmaceuticals North America LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
P72951562000P2950000
application(s)

forensics and toxicology

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

-

technique(s)

-

form

liquid

form

-

form

-

form

-

Quality Level

300

Quality Level

100

Quality Level

-

Quality Level

-

grade

certified reference material

grade

analytical standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

storage temp.

−20°C

storage temp.

-

storage temp.

-

storage temp.

2-8°C


signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup



Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Nancy L Diaz et al.
Parkinsonism & related disorders, 16(9), 604-607 (2010-08-10)
Although small treatment trials have examined the efficacy of front-line medications in tremor reduction in essential tremor (ET), an overall survey of pharmacological management has not been undertaken in a large sample of ET cases. To conduct a survey of
Günther Deuschl et al.
The Lancet. Neurology, 10(2), 148-161 (2011-01-25)
Essential tremor is a common movement disorder. Tremor severity and handicap vary widely, but most patients with essential tremor do not receive a diagnosis and hence are never treated. Furthermore, many patients abandon treatment because of side-effects or poor efficacy.
Bradley N Gaynes et al.
Psychiatric services (Washington, D.C.), 60(11), 1439-1445 (2009-11-03)
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms



Global Trade Item Number

SKUGTIN
P-075-1ML04061834253877

Questions

Reviews

No rating value

Active Filters